Celyad Oncology S.A.

CYAD · NASDAQ
Analyze with AI
12/31/2024
6/30/2024
12/31/2023
6/30/2023
Operating Activities
Net Income-$3,044-$4,708-$3,740
Dep. & Amort.$229$397$397
Deferred Tax$0$0-$1,238
Stock-Based Comp.$6$491$444
Change in WC$306$2,394-$3,599
Other Non-Cash-$328-$5,445-$595
Operating Cash Flow-$2,831-$6,871-$8,331
Investing Activities
PP&E Inv.$0-$583-$350
Net Acquisitions$0$26$1,315
Inv. Purchases$0$0$0
Inv. Sales/Matur.$0$0$0
Other Inv. Act.-$118$25$1,281
Investing Cash Flow-$118-$558$965
Financing Activities
Debt Repay.-$83$0-$92
Stock Issued$0$9,490$0
Stock Repurch.$0$10-$10
Dividends Paid$0$0$0
Other Fin. Act.$2,258$9,457$0
Financing Cash Flow$2,175$9,457-$102
Forex Effect$0$0-$1
Net Chg. in Cash$6,229$2,028-$7,469
Supplemental Information
Beg. Cash$0$4,976$12,445
End Cash$6,229$7,004$4,976
Free Cash Flow-$2,831-$7,454-$8,681